This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
2024 Diabetes Kidney Disease 
HCPLive
OCTOBER 27, 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
133 
The British Journal of Cardiology
OCTOBER 8, 2024
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.
40 
GEMMS
MAY 22, 2024
Gene-Based Analysis Predictive analytics is vital in reducing morbidity and mortality, with healthcare startups focusing on early risk prediction and disease detection. Much of heart disease is linked to conditions like diabetes, obesity, or chronic kidney disease, and specific mutations in nucleic acids help identify them.
DAIC
JANUARY 18, 2024
Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform.
105 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP278-AWP278, February 1, 2024. Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE.
40 
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4137914-A4137914, November 12, 2024. This included an HbA1c>7.0%, age>50 with established CVD, heart failure, or chronic kidney disease or an age>60 with at least one CVD risk factor. year follow-up time).Results:Among Results:Among 5002 (projected to 34.0
40 
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
52 
Cardiometabolic Health Congress
AUGUST 14, 2024
14, 2024 (GLOBE NEWSWIRE) — For nearly two decades, Dr. George L. Taking place October 17-19, 2024, at The Boston Park Plaza, MA, this is a must-attend event for healthcare professionals across all specialties and sectors. Bakris’ distinguished career as a leading educator and mentor. Boca Raton, FL, Aug.
72 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141474-A4141474, November 12, 2024. Logistic regression was used to determine the association between 5-HTP levels and calcification severity, adjusting for age, gender, smoking status, chronic kidney disease, hyperlipidemia, and diabetes. to 1.10); diabetes 1.24 (0.67
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. More recently, the nonsteroidal MRA finerenone improved the HF outcomes of patients with HF with preserved ejection fraction, expanding the benefits previously seen among patients with diabetes and albuminuric chronic kidney disease.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4113864-A4113864, November 12, 2024. Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001).
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4148106-A4148106, November 12, 2024. Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The hemophilia cohort was slightly older (63.2[16.8]
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4145609-A4145609, November 12, 2024. Introduction:Cannabis has been increasingly used as a recreational drug. Its cardiovascular effects depend on several factors, including the exact composition, route of administration, dose, and duration of use.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146863-A4146863, November 12, 2024. Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page A52-A52, February 1, 2024. million by 2030 according to the Global Burden of Disease Study. Autoimmune diseases are increasingly associated with chronic conditions and may modify risks by altering underlying pathophysiology. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4147960-A4147960, November 12, 2024. of patients had cardiovascular disease, 10.9% diabetes, and 15.5% chronic kidney disease. The results were reported as the pooled results using risk ratio (RR) and a confidence interval (CI) of 95%.Results:The
Dr. Smith's ECG Blog
SEPTEMBER 5, 2024
A VSR is more likely to occur in patients who are older, female, hypertensive, have chronic kidney disease, and have no prior history of smoking. It commonly occurs in the setting of a first myocardial infarction (MI) in the background of delayed or absent reperfusion therapy. Hammill SC. Edwards WD.
The British Journal of Cardiology
MARCH 7, 2024
The Cardiorenal Forum’s recent 18 th Annual Scientific meeting looked at the latest updates in the failing heart and kidney. Dr Mohammad Wasef and Dr Sarah Birkhoelzer report its highlights.
40 
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). In fact, a 2024 report on heart failure trends and outcomes published in the Journal of Cardiac Failure showed that in patients with heart failure with preserved ejection fraction, 5-year mortality was 75.7%.
Cardiometabolic Health Congress
JULY 17, 2024
The first half of 2024 has ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery.
59 
Cardiometabolic Health Congress
SEPTEMBER 13, 2024
The European Society of Cardiology (ESC) Congress 2024 (August 30 – September 2, 2024) has wrapped up, delivering groundbreaking insights into cardiovascular diseases and related conditions. Measuring eGFR and albuminuria is recommended for assessing kidney disease in all hypertensive patients.
59 
DAIC
SEPTEMBER 11, 2024
tim.hodson Wed, 09/11/2024 - 15:40 Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San Francisco (UCSF) report that 10.5 million Americans have atrial fibrillation. million U.S. adults, according to new estimates from University of California-San Francisco. million U.S.
DAIC
JANUARY 19, 2024
milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. and Europe. billion adults worldwide.
105 
CardiacWire
OCTOBER 27, 2024
It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. A JAMA analysis of 11k adults revealed that only 10.6%
59 
DAIC
APRIL 7, 2024
mtaschetta-millane Sun, 04/07/2024 - 18:43 April 7. In a randomized study published in March 2024, patients with elevated blood pressure who were treated with zilebesiran alone saw their systolic blood pressure fall by up to 14.5 Approximately 1 in 4 patients had diabetes other than Type 1 in addition to high blood pressure.
111 
DAIC
APRIL 6, 2024
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP160-AWP160, February 1, 2024. Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
CardiacWire
OCTOBER 6, 2024
Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects.
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death.
105 
DAIC
APRIL 6, 2024
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4139313-A4139313, November 12, 2024. Predictors of high-risk of advanced liver fibrosis, included older age, male sex, severe chronic kidney disease, previous myocardial infarction, ischemic heart disease, and atrial fibrillation/flutter.
DAIC
SEPTEMBER 11, 2024
tim.hodson Wed, 09/11/2024 - 15:40 Sept. A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. million Americans have atrial fibrillation. million U.S. million U.S. The study appears Sept.
Cardiometabolic Health Congress
JANUARY 19, 2024
Short history from development to today’s price hikes Doctors Frederick Banting and Charles Best successfully isolated the hormone insulin just over 100 years ago, dramatically changing the lives of those with diabetes. million Americans with diabetes need to inject insulin to survive, according to the American Diabetes Association.
59 
Cardiometabolic Health Congress
JULY 10, 2024
Bakris , an internationally recognized and influential nephrologist and hypertension expert, who passed away on June 15, 2024, at the age of 72. Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression.
52 
Journal of Cardiovascular Pharmacology
DECEMBER 11, 2024
To compare the efficacy of SGLT2 inhibitors among non-older and older patients we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials (RCTs) investigating SGLT2 inhibitors in older (age 65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure.
DAIC
MAY 16, 2024
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).
Circulation: Cardiovascular Imaging
JANUARY 15, 2024
Circulation: Cardiovascular Imaging, Volume 17, Issue 1 , Page e015858, January 1, 2024. BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. years post-transplant. A minority had abnormal MPI (n=58, 15%). 2.66];P=0.33).
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024. Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure.
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP269-AWP269, February 1, 2024. Background:Research suggests that residing in a food desert (FD) area may negatively impact health by increasing cardiovascular risk factors.
40 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page ATP205-ATP205, February 1, 2024. Background and Purpose:Large vessel occlusion secondary to intracranial atherosclerotic disease (ICAD-LVO) has an estimated prevalence of 10-30%. women; mean age, 69.1 [SD, years; mean NIHSS score of 15.1 [SD, years; mean NIHSS score of 13.8 [SD,
40 
DAIC
JANUARY 23, 2024
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 Anti- inflammatory Therapy for Cardiovascular Disease. Elsevier; 2024:224-235. μ/L on 0.6
DAIC
APRIL 4, 2024
Early coronary disease and impaired heart function, with increased coronary vessel wall thickness, in asymptomatic, middle-aged individuals living with HIV has been reported in a new study published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA). Gharib, M.D.
Cardiometabolic Health Congress
DECEMBER 17, 2024
Regular assessment of eGFR and UACR, particularly in high-risk populations such as those with diabetes or hypertension, provides crucial insights into patient health. Updated guidelines recommend using these markers to guide decisions on therapy, including statin use in patients with mildly reduced kidney function.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content